Personalized Cancer Vaccines Made From Your Tumor's Own Mutations

This is a narrative review published in Theranostics that synthesizes the history of peptide-based cancer vaccines, the scientific rationale for using long peptides over short peptides, the advantages of neoantigen targeting, and current preclinical and clinical developments in the field.

Cancer immunotherapy has been revolutionized by checkpoint inhibitors, but many patients don't respond. Personalized neoantigen vaccines could complement these treatments by training the immune system to recognize each patient's specific tumor mutations. Long peptide formats are emerging as the preferred delivery platform because they generate broader, more durable immune responses than short peptides — and synthetic peptides are faster and cheaper to manufacture than other vaccine formats.

Personalized neoantigen vaccines sit at the intersection of genomics, immunology, and peptide science. As DNA sequencing costs plummet, identifying each patient's unique tumor mutations has become routine. The challenge is turning that genomic data into effective vaccines fast enough to treat patients. Synthetic long peptides offer a practical manufacturing platform, and when combined with checkpoint inhibitors, may dramatically expand the proportion of cancer patients who benefit from immunotherapy.

As a review, no new data is presented. The field is still early-stage — most clinical trials are small, single-arm studies without randomized comparisons. Manufacturing personalized vaccines is time-consuming and expensive. Not all predicted neoantigens generate meaningful immune responses. Tumors can evolve to lose the targeted mutations (immune escape). The optimal adjuvant, dosing schedule, and combination strategies remain undefined.